BrainsGate

BrainsGate
Name	BrainsGate
Type	Private
Industry	Medical devices
Founded	2003
Founder	Jacob (Yaakov) Ramon
Headquarters	Israel
Products	Neurostimulation devices

BrainsGate BrainsGate is an Israeli biomedical company developing minimally invasive neuromodulation therapies for cerebrovascular disorders. The firm focuses on electrical stimulation technologies intended to augment cerebral blood flow in acute and chronic stroke conditions and related ischemic pathologies. Its work intersects with research institutions, hospitals, and regulatory agencies across Israel, United States, European Union, and other markets.

History and company overview

BrainsGate was founded in the early 2000s and evolved through collaborations with academic centers and clinical investigators in Tel Aviv University, Weizmann Institute of Science, and Hadassah Medical Center. Early development drew on research by neuroscientists and clinicians associated with Hebrew University of Jerusalem, Technion – Israel Institute of Technology, and the Bar-Ilan University medical research community. The company has engaged with venture capital firms, angel investors, and global strategic partners including entities from Silicon Valley, New York City, Boston, London, and Munich. Leadership and advisory boards have included neurologists and interventionalists affiliated with Massachusetts General Hospital, Johns Hopkins Hospital, Cleveland Clinic, and Sheba Medical Center. Over time BrainsGate pursued regulatory pathways with the U.S. Food and Drug Administration, European Medicines Agency, and national authorities in Israel and other jurisdictions.

Technology and medical device

The company’s principal device is a catheter-based neuromodulation system designed to deliver targeted electrical stimulation to parasympathetic or cranial nerve-related structures to promote cerebral perfusion. The technology builds on foundational science from laboratories such as MIT, Harvard Medical School, Stanford University, and UCSF, and draws on prior work in neurovascular modulation performed at centers including Imperial College London, Karolinska Institutet, and McGill University. Engineering and biomaterials support came from collaborations with institutes like Technion – Israel Institute of Technology and firms in Silicon Valley and Germany. The device’s design reflects advances in interventional radiology and endovascular techniques refined at Mayo Clinic, Mount Sinai Hospital (New York), and Vanderbilt University Medical Center.

Clinical trials and regulatory status

BrainsGate conducted multiple clinical studies including randomized controlled trials and feasibility studies in acute ischemic stroke and chronic cerebrovascular insufficiency, registering trials with institutions such as Sheba Medical Center, Rambam Health Care Campus, Assaf Harofeh Medical Center, Barzilai Medical Center, and collaborating with international stroke centers like Royal Prince Alfred Hospital, Toronto General Hospital, and Charité – Universitätsmedizin Berlin. The company has sought market authorization routes involving the European Medicines Agency CE marking process and engaged with the U.S. Food and Drug Administration for investigational device exemptions. Clinical investigators included specialists from Mount Sinai Hospital (Toronto), University College London Hospitals, Johns Hopkins Hospital, and Guy's and St Thomas' NHS Foundation Trust. Study endpoints and statistical plans referenced methodologies from NINDS, ESO, and other stroke trial consortia.

Indications and clinical application

The primary indications explored are acute ischemic stroke refractory to or adjunctive with reperfusion therapies such as thrombolysis and mechanical thrombectomy, and chronic conditions involving cerebral hypoperfusion including vascular cognitive impairment evaluated in memory clinics affiliated with Mayo Clinic, Alzheimer's Association research networks, and university centers like Oxford University and UCSF. Applications have been assessed in inpatient stroke units at Massachusetts General Hospital, Royal Melbourne Hospital, Singapore General Hospital, and rehabilitation programs at Spaulding Rehabilitation Hospital and Rehabilitation Institute of Chicago. The technology has been positioned as complementary to existing acute stroke pathways developed by organizations such as American Heart Association and European Stroke Organisation.

Safety and adverse effects

Safety assessments in trials monitored procedure-related complications analogous to those reported in endovascular interventions at centers like Cleveland Clinic and NYU Langone Health. Adverse events catalogued included site-specific effects, transient neurological changes, and device- or procedure-related infections, managed per protocols used in trials overseen by ethics committees from Sheba Medical Center, Guy's and St Thomas' NHS Foundation Trust, and Charité – Universitätsmedizin Berlin. Monitoring frameworks referenced guidance from regulatory bodies including U.S. Food and Drug Administration, European Medicines Agency, and national health ministries. Post-procedure surveillance and risk mitigation strategies paralleled those in interventional neuroradiology programs at Mount Sinai Hospital (New York) and Johns Hopkins Hospital.

Commercialization and partnerships

BrainsGate pursued commercialization through partnerships with medical device distributors, hospital systems, and strategic alliances with biotechnology firms in United States, Europe, and Asia. Collaborative agreements and licensing discussions involved clinical device manufacturers and investors in regions such as California, Massachusetts, Germany, United Kingdom, and Japan. The company engaged with procurement organizations at tertiary hospitals like Sheba Medical Center, Mayo Clinic, Cleveland Clinic, and health technology assessment bodies associated with NHS England and national agencies in Germany and France. Ongoing commercial strategy referenced collaborations with academic trial networks including NIH-funded consortia, multinational clinical research organizations, and private equity investors in Tel Aviv and New York City.

Category:Medical device companies